A phase II trial of m-AMSA in patients with small-cell lung cancer.
Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.
D000368:Aged; D000609:Aminoacridines / Q000009:adverse effects / Q000627:therapeutic use*; D000677:Amsacrine; D001853:Bone Marrow / Q000187:drug effects; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000609:Aminoacridines; D000677:Amsacrine